NefIgArd
2023
Nefecon in Patients with Primary IgA Nephropathy
In 364 patients with IgA nephropathy on optimised RAS blockade, targeted-release budesonide preserved eGFR and reduced proteinuria compared with placebo.
Result
Primary endpoint: Time-weighted eGFR over 2 years
+5.1 mL/min/1.73m² versus placebo (p<0.001); proteinuria reduced 41%.
- Subtopic
- IgA nephropathy
- Design
- Phase 3 double-blind RCT
- Relevance
- Important: one of several pillars.
- Cited in
- KDIGO 2025 IgA Nephropathy
- Source
- Lafayette R, et al. Lancet. 2023;402(10405):859-870.doi 10.1016/S0140-6736(23)01554-4
Discussion & critique
Led to full FDA approval of Tarpeyo; off-drug follow-up and steroid-type adverse effects temper enthusiasm.